The Potential Role of Urinary Microbiota in Bladder Carcinogenesis: A Systematic Review
Urology Journal,
Vol. 20 (2023),
25 December 2022
,
Page 8036
https://doi.org/10.22037/uj.v20i.8036
Abstract
Purpose: The quantitative objective of the current systematic review was to identify the potential role of urinary microbiota in bladder cancer (BC) carcinogenesis, invasiveness, progression, and metastasis.
Materials and Methods: The proposed systematic review was conducted in accordance with critical review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement, and the Joanna Briggs Institute (JBI) methodology for systematic reviews. The search strategy aimed to find both published and unpublished studies up to the January 2024. A JBI appraisal checklist was used to assess possible biases.
Results: This systematic review was centered on 27 studies comprising 926 BC patients. Overall, 412 control individuals were compared with BC patients. The most common sampling method was midstream urine collection. Regarding microbial alpha diversity, there was no statistically significant difference between cancerous and healthy samples (n=8), recurrent and not recurrent (n=1), responders versus non-responders(n=1), tumor grades (n=1), and collection methods (n=1). However, five studies reported higher diversity in controls, and five other studies reported, conversely, high levels of alpha diversity in BC patients or recurrent cases. Furthermore, a responder (RE) to treatment and a non-muscle invasive bladder cancer (NMIBC) groups demonstrated significant difference with non-responder (NR) and muscle invasive bladder cancer (MIBC), respectively. In terms of beta-diversity, nine studies reported significant diversity between BC patients and controls, one article demonstrated difference between recurrent and not recurrent patients, a study reported significant difference in RE and NR groups whereas another showed opposite, and others (n=4) did not find any difference between BC, controls, MIBC and NMIBC patients, or between tumor grades. One study reported a difference between the collection method and beta-diversity in males and another reported the difference in females.
Conclusion: The included studies demonstrate that the composition of urinary microbiota is altered in patients with BC. However, the differentially enriched genera in the urine of these patients vary between studies, and there is too much heterogeneity across studies to make any reliable and valid conclusions. Furthermore, well-designed research is necessary to assess the role of microbiota in the carcinogenesis and progression of BC.
- Microbiota
- Microbiome
- Urinary Bladder Neoplasms
- Systematic Review
How to Cite
References
[]
Weinstock GM. Genomic approaches to studying the human microbiota. Nature. 2012;489:250-6.
Aragón IM, Herrera-Imbroda B, Queipo-Ortuño MI, et al. The Urinary Tract Microbiome in Health and Disease. Eur Urol Focus. 2018;4:128-38.
Brubaker L, Wolfe AJ. The female urinary microbiota, urinary health and common urinary disorders. Ann Transl Med. 2017;5:34.
Antunes-Lopes T, Vale L, Coelho AM, et al. The Role of Urinary Microbiota in Lower Urinary Tract Dysfunction: A Systematic Review. Eur Urol Focus. 2020;6:361-9.
Bersanelli M, Santoni M, Ticinesi A, Buti S. The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. Target Oncol. 2019;14:247-52.
Sung H, Ferlay J, Siegel RL. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71:209-49.
Rozanec JJ, Secin FP. [Epidemiology, etiology and prevention of bladder cancer.]. Arch Esp Urol. 2020;73:872-8.
Mancini M, Righetto M. Spotlight on gender-specific disparities in bladder cancer. 2020;87:103-14.
Bi H, Tian Y, Song C, et al. Urinary microbiota - a potential biomarker and therapeutic target for bladder cancer. J Med Microbiol. 2019;68:1471-8.
Hourigan SK, Zhu W, S.W.Wong W, et al. Studying the urine microbiome in superficial bladder cancer: samples obtained by midstream voiding versus cystoscopy. BMC Urology. 2020;20:5.
Mansour B, Monyók Á, Makra N, et al. Bladder cancer-related microbiota: examining differences in urine and tissue samples. Scientific Reports. 2020;10:11042.
Chipollini J, Wright JR, Nwanosike H, et al. Characterization of urinary microbiome in patients with bladder cancer: Results from a single-institution, feasibility study. Urologic Oncology: Seminars and Original Investigations. 2020;38:615-21.
Zeng J, Zhang G, Chen C, et al. Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study. Front Cell Infect Microbiol. 2020;10:555508.
Hussein AA, Elsayed AS, Durrani M, et al. Investigating the association between the urinary microbiome and bladder cancer: An exploratory study. Urol Oncol. 2021;39:370.e9-.e19.
Pederzoli F, Ferrarese R, Amato V, et al. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. Eur Urol Oncol. 2020;3:784-8.
Bučević Popović V, Šitum M, Chow CT, Chan LS, Roje B, Terzić J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8:12157.
Wu P, Zhang G, Zhao J, et al. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:167.
Oresta B, Braga D, Lazzeri M, et al. The Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage. J Urol. 2021;205:86-93.
Mansour B, Monyók Á, Gajdács M, et al. Bladder tissue microbiome composition in patients of bladder cancer or benign prostatic hyperplasia and related human beta defensin levels. Biomedicines. 2022;10:1758.
Hrbáček J, Tláskal V, Čermák P, Hanáček V, Zachoval R. Bladder cancer is associated with decreased urinary microbiota diversity and alterations in microbial community composition; 2023.
Qin C, Chen Z, Cao R, Shi M, Tian Y. Integrated Analysis of the Fecal Metagenome and Metabolome in Bladder Cancer in a Chinese Population. Genes. 2022;13:1967.
Parra-Grande M, Oré-Arce M, Martínez-Priego L, et al. Profiling the bladder microbiota in patients with bladder cancer. Frontiers in Microbiology. 2022;12:718776.
Liu F, Liu A, Lu X, et al. Dysbiosis signatures of the microbial profile in tissue from bladder cancer. Cancer Med. 2019;8:6904-14.
Ozer MS, Yildiz HA, Incir C, et al. Urinary microbiota; Which non‐ınvasive urine collection method should we use? International Journal of Clinical Practice. 2021;75:e14193.
Mai G, Chen L, Li R, Liu Q, Zhang H, Ma Y. Common core bacterial biomarkers of bladder cancer based on multiple datasets. BioMed research international. 2019;2019:4824909.
Zhang Y, Wang W, Zhou H, Cui Y. Urinary Eubacterium sp. CAG: 581 Promotes Non-Muscle Invasive Bladder Cancer (NMIBC) Development through the ECM1/MMP9 Pathway. Cancers. 2023;15:809.
Sun J-X, Xia Q-D, Zhong X-Y, Liu Z, Wang S-G. The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M. Frontiers in Cellular and Infection Microbiology. 2023;13:1182322.
Qiu Y, Gao Y, Chen C, et al. Deciphering the influence of urinary microbiota on FoxP3+ regulatory T cell infiltration and prognosis in Chinese patients with non-muscle-invasive bladder cancer. Human Cell. 2022;35:1-11.
Bukavina L, Calaway AC, Isali I, et al. Characterization and functional analysis of microbiome in bladder cancer: American Society of Clinical Oncology; 2022.
Knorr J, Werneburg G, Adler A, et al. Pd12-01 bladder tumor microbiome may augment response to BCG in non-muscle invasive bladder cancer. The Journal of Urology. 2022;207:e195.
Houenstein H, Ramahi Y, Shah AA, et al. MP59-07 DOES THE URINARY MICROBIOME PROFILE CHANGE AFTER TREATMENT OF BLADDER CANCER? The Journal of Urology. 2022;207:e1003.
Pederzoli F, Locatelli I, Riba M, et al. PD42-05 FECAL MICROBIOTA PROFILING OF PATIENTS TREATED WITH NEOADJUVANT PEMBROLIZUMAB FOR MUSCLE INVASIVE UROTHELIAL CARCINOMA. The Journal of Urology. 2021;206:e726-e.
Sweis* R, Golan S, Barashi N, et al. MP43-11 CHARACTERIZATION OF THE URINARY MICROBIOME IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUéRIN IMMUNOTHERAPY. The Journal of Urology. 2019;201:e621-e.
Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71:96-108.
Kluth LA, Black PC, Bochner BH, et al. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015;68:238-53.
Tilki D, Burger M, Dalbagni G, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011;60:484-92.
Putluri N, Shojaie A, Vasu VT, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 2011;71:7376-86.
Gontero P, Sylvester R, Pisano F, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients. Eur Urol. 2015;67:74-82.
Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12:7369-73.
Kluth LA, Rieken M, Xylinas E, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol. 2014;66:913-9.
Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011;108:24-30.
- Abstract Viewed: 127 times
- Just Accepted-8036 Downloaded: 86 times